Patent ID: 6534510
Filing Date: 2003-03-18
Classification: A61P,C07D

Abstract:
A compound of the formula or a pharmaceutically acceptable salt thereof, whereinT is selected from the group consisting of D, E, F, G, H, I, and J are independently N or C Y1, provided that the number of such variables D, E, F, G, H, I, and J representing N is 0, 1, or 2; K, L, M and Q are independently NH or C Y1Y2, provided that the number of such variables D, E, F, K, L, M, and Q representing N is 0, 1, or 2; Y1 and Y2 are independently selected from the group consisting of hydrogen, C1-4 alkyl, halogen, amino, or hydroxy; A is W is hydrogen, R1, R1OCO, R1CO, R1S02, R1(CH2)nNHCO, or (R1)2CH(CH2)nNHCO, wherein n is 0-4; R1 is R2,R2(CH2)mC(R12)2, where m is 0-3, and each R12 can be the same or different, (R2)(OR2)CH(CH2)p, where p is 1-4, â€ƒwhere m is 0-3, R2C(R12)2(CH2)m, wherein m is 0-3, and each R12 can be the same or different, wherein (R12)2 can also form a ring with C represented by C3-7 cycloalkyl, R2CH2C(R12)2(CH2)q, wherein q is 0-2, and each R12 can be the same or different, wherein (R12)2 can also form a ring with C represented by C3-7 cycloalkyl, (R2)2CH(CH2)r, where r is 0-4 and each R2 can be the same or different, and wherein (R2)2 can also form a ring with CH represented by C3-7 cycloalkyl, C7-12 bicylic alkyl, C10-16 tricylic alkyl, or a 5- to 7-membered mono- or bicyclic heterocyclic ring which can be saturated or unsaturated, and which consists of from one to three heteroatoms selected from the group consisting of N, O and S, R2(CH2)tO(CH2)p, wherein t is 0 or 1 and p is 1-4, R2CF2C(R12)2, (R2CH2)(R2CH2)Nâ€”, (R2CH2)(R2CH2)CH, or R2(COOR3)(CH2)r, where r is 1-4; R2 and R4 are independently phenyl, unsubstituted or substituted with one or more of C1-4 alkyl, C1-4 alkoxy, halogen, hydroxy, COOH, CONH2, CH2OH, CO2Râ€², where Râ€² is C1-4 alkyl, or SO2NH2, naphthyl, biphenyl, pyridine N-oxide, a 5- to 7-membered mono- or a 9- to 10-membered bicyclic a) non-heterocyclic ring system, which is saturated or unsaturated, and which is unsubstituted or substituted with halogen or hydroxy, or b) heterocyclic ring system, which is saturated or unsaturated, having carbon ring atoms and heteroatom ring atoms, wherein the ring system consists of i) from one to four heteroatoms selected from the group consisting of N, O, and S, and wherein the ring system is unsubstituted, or ii) from one to four nitrogen atoms, wherein one or more of the carbon and nitrogen ring atoms are substituted with halogen or hydroxy, C1-7 alkyl, unsubstituted or substituted with one or more of hydroxy, COOH, amino, aryl, C3-7 cycloalkyl, CF3, N(CH3)2, â€”C1-3alkylaryl, heteroaryl, or heterocycloalkyl, CF3 C3-7 cycloalkyl, unsubstituted or substituted with aryl, C7-12 bicyclic alkyl, or C10-16 tricyclic alkyl; R3, R5 and R6are independently selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C3-7 cycloalkyl, or trifluoromethyl; X is hydrogen, or halogen; Z is CH2, S, or SO2; R12 is hydrogen, phenyl, unsubstituted or substituted with one or more of C1-4 alkyl, C1-4 alkoxy, halogen, hydroxy, COOH, CONH2, naphthyl, biphenyl, a 5- to 7-membered mono- or a 9- to 10-membered bicyclic heterocyclic ring which can be saturated or unsaturated, and which consists of from one to four heteroatoms selected from the group consisting of N, O and S, C1-4 alkyl, unsubstituted or substituted with one or more of hydroxy, OH, COOH, amino, â€”N(CH3)2, â€”NH(CH3), â€”N(CH2)COOH, aryl, heteroaryl, or heterocycloalkyl, CF3 C3-7 cycloalkyl, C7-12 bicyclic alkyl, or C10-16 tricyclic alkyl.